Financial news, corporate announcements, analysts’ reports
LONDON: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather…
LONDON: AstraZeneca today announced $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the…
LONDON: AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of the decade. To drive sustained growth…
LONDON: AstraZeneca has unveiled plans to construct a state-of-the-art manufacturing facility in Singapore, dedicated to the production of antibody drug conjugates (ADCs). This $1.5 billion venture marks the company’s first foray into manufacturing within Singapore and represents a significant step in enhancing the global supply of its ADC portfolio. ADCs, which are at the forefront…
AstraZeneca has completed a $140 million equity investment in Cellectis, a biotech firm at the forefront of gene-editing therapies. This transaction, which follows approval from the French Ministry of Economy, sees AstraZeneca acquiring 10 million Class A and 18 million Class B convertible preferred shares at $5 each. The Class A shares carry single voting…
LONDON: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca’s drug Truqap, in combination with Faslodex, for treating certain advanced breast cancer cases. The positive opinion is based on the CAPItello-291 Phase III trial results, which showed a 50% reduction in disease progression or death compared…
LONDON: AstraZeneca has kicked off the year with a remarkable 19% increase in Total Revenue, reaching $12.679 billion in the first quarter of 2024. The pharmaceutical giant attributes this surge to an 18% rise in Product Sales and sustained growth in Alliance Revenue from its partnered medicines. The company’s financial health is further evidenced by…
LONDON: ANGLE plc (AIM:AGL), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE’s existing DNA damage response (“DDR”) assay for the detection of…
LONDON: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs…
AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis.…
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase in core earnings per share. The company’s total revenue reached $45,811 million, up from $43,075 million in 2022, despite a decline of $3,736 million from COVID-19 medicines. Excluding COVID-19 medicines,…
Acquisition of Gracell completed AstraZeneca has agreed to acquire Gracell Biotechnologies, a company developing cell therapies for cancer and autoimmune diseases, for up to $1.2bn. The deal will add GC012F, a dual-targeting CAR-T therapy for multiple myeloma, to AstraZeneca’s portfolio of cell therapies. Gracell Biotechnologies will operate as a wholly owned subsidiary of AstraZeneca, with…